Bioventus Stock EBITDA

BVS Stock

USD 11.51 0.10 0.88%

Bioventus fundamentals help investors to digest information that contributes to Bioventus' financial success or failures. It also enables traders to predict the movement of Bioventus Stock. The fundamental analysis module provides a way to measure Bioventus' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Bioventus stock.

		Last Reported	Projected for Next Year
	EBITDA	-23.1 M	-21.9 M

EBITDA is likely to gain to about (21.9 M) in 2024.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Bioventus Company EBITDA Analysis

Bioventus' EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.

EBITDA

Revenue

-

Basic Expenses

More About EBITDA | All Equity Analysis

Current Bioventus EBITDA

(23.07 M)

Most of Bioventus' fundamental indicators, such as EBITDA, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Bioventus is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Bioventus EBITDA Driver Correlations

Understanding the fundamental principles of building solid financial models for Bioventus is extremely important. It helps to project a fair market value of Bioventus Stock properly, considering its historical fundamentals such as EBITDA. Since Bioventus' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Bioventus' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Bioventus' interrelated accounts and indicators.

	Total Assets	Total Stockholder Equity	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Net Receivables	Good Will	Total Liab	Total Current Assets	Short Term Debt	Intangible Assets	Common Stock	Net Tangible Assets	Property Plant Equipment	Long Term Debt	Net Invested Capital	Long Term Investments	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Investments	Capital Surpluse	Deferred Long Term Liab
Total Assets		0.86	0.17	0.9	-0.22	0.9	0.87	0.11	0.97	0.82	0.65	0.97	-0.66	-0.57	0.71	0.92	0.97	0.43	0.86	-0.89	-0.7	-0.23	-0.23	-0.23
Total Stockholder Equity	0.86		0.44	0.69	0.19	0.58	0.6	0.53	0.72	0.54	0.45	0.79	-0.67	-0.69	0.5	0.7	0.9	0.63	0.52	-0.72	-0.44	-0.08	-0.08	-0.08
Current Deferred Revenue	0.17	0.44		-0.13	0.44	-0.2	0.21	0.85	0.03	0.27	-0.08	-0.03	0.23	0.24	0.24	-0.06	0.22	0.92	-0.06	0.01	0.33	0.36	0.36	0.36
Net Debt	0.9	0.69	-0.13		-0.4	0.94	0.81	-0.11	0.91	0.75	0.72	0.91	-0.77	-0.65	0.66	0.98	0.9	0.16	0.87	-0.93	-0.61	-0.38	-0.38	-0.38
Retained Earnings	-0.22	0.19	0.44	-0.4		-0.46	-0.54	0.73	-0.35	-0.56	-0.42	-0.18	0.14	-0.16	-0.41	-0.47	-0.22	0.28	-0.6	0.52	0.19	0.79	0.79	0.79
Accounts Payable	0.9	0.58	-0.2	0.94	-0.46		0.84	-0.26	0.96	0.78	0.69	0.94	-0.6	-0.5	0.62	0.93	0.83	0.05	0.91	-0.85	-0.8	-0.3	-0.3	-0.3
Net Receivables	0.87	0.6	0.21	0.81	-0.54	0.84		-0.04	0.9	0.99	0.61	0.77	-0.38	-0.16	0.8	0.88	0.86	0.42	0.92	-0.87	-0.51	-0.37	-0.37	-0.37
Good Will	0.11	0.53	0.85	-0.11	0.73	-0.26	-0.04		-0.09	-0.04	-0.17	-0.02	0.06	-0.11	-0.05	-0.12	0.19	0.75	-0.3	0.1	0.34	0.49	0.49	0.49
Total Liab	0.97	0.72	0.03	0.91	-0.35	0.96	0.9	-0.09		0.85	0.67	0.96	-0.59	-0.47	0.72	0.92	0.91	0.28	0.92	-0.87	-0.79	-0.26	-0.26	-0.26
Total Current Assets	0.82	0.54	0.27	0.75	-0.56	0.78	0.99	-0.04	0.85		0.57	0.69	-0.33	-0.07	0.83	0.83	0.81	0.47	0.9	-0.84	-0.43	-0.38	-0.38	-0.38
Short Term Debt	0.65	0.45	-0.08	0.72	-0.42	0.69	0.61	-0.17	0.67	0.57		0.65	-0.61	-0.4	0.65	0.69	0.6	0.15	0.72	-0.67	-0.43	-0.36	-0.36	-0.36
Intangible Assets	0.97	0.79	-0.03	0.91	-0.18	0.94	0.77	-0.02	0.96	0.69	0.65		-0.7	-0.67	0.6	0.9	0.91	0.23	0.83	-0.83	-0.83	-0.18	-0.18	-0.18
Common Stock	-0.66	-0.67	0.23	-0.77	0.14	-0.6	-0.38	0.06	-0.59	-0.33	-0.61	-0.7		0.9	-0.5	-0.75	-0.71	-0.1	-0.59	0.76	0.43	0.46	0.46	0.46
Net Tangible Assets	-0.57	-0.69	0.24	-0.65	-0.16	-0.5	-0.16	-0.11	-0.47	-0.07	-0.4	-0.67	0.9		-0.16	-0.58	-0.61	0.01	-0.32	0.56	0.47	0.2	0.2	0.2
Property Plant Equipment	0.71	0.5	0.24	0.66	-0.41	0.62	0.8	-0.05	0.72	0.83	0.65	0.6	-0.5	-0.16		0.73	0.7	0.48	0.86	-0.74	-0.29	-0.35	-0.35	-0.35
Long Term Debt	0.92	0.7	-0.06	0.98	-0.47	0.93	0.88	-0.12	0.92	0.83	0.69	0.9	-0.75	-0.58	0.73		0.93	0.24	0.92	-0.97	-0.59	-0.47	-0.47	-0.47
Net Invested Capital	0.97	0.9	0.22	0.9	-0.22	0.83	0.86	0.19	0.91	0.81	0.6	0.91	-0.71	-0.61	0.7	0.93		0.48	0.82	-0.94	-0.56	-0.34	-0.34	-0.34
Long Term Investments	0.43	0.63	0.92	0.16	0.28	0.05	0.42	0.75	0.28	0.47	0.15	0.23	-0.1	0.01	0.48	0.24	0.48		0.23	-0.3	0.13	0.14	0.14	0.14
Short Long Term Debt	0.86	0.52	-0.06	0.87	-0.6	0.91	0.92	-0.3	0.92	0.9	0.72	0.83	-0.59	-0.32	0.86	0.92	0.82	0.23		-0.89	-0.64	-0.46	-0.46	-0.46
Capital Stock	-0.89	-0.72	0.01	-0.93	0.52	-0.85	-0.87	0.1	-0.87	-0.84	-0.67	-0.83	0.76	0.56	-0.74	-0.97	-0.94	-0.3	-0.89		0.52	0.61	0.61	0.61
Net Working Capital	-0.7	-0.44	0.33	-0.61	0.19	-0.8	-0.51	0.34	-0.79	-0.43	-0.43	-0.83	0.43	0.47	-0.29	-0.59	-0.56	0.13	-0.64	0.52		0.1	0.1	0.1
Short Term Investments	-0.23	-0.08	0.36	-0.38	0.79	-0.3	-0.37	0.49	-0.26	-0.38	-0.36	-0.18	0.46	0.2	-0.35	-0.47	-0.34	0.14	-0.46	0.61	0.1		1.0	1.0
Capital Surpluse	-0.23	-0.08	0.36	-0.38	0.79	-0.3	-0.37	0.49	-0.26	-0.38	-0.36	-0.18	0.46	0.2	-0.35	-0.47	-0.34	0.14	-0.46	0.61	0.1	1.0		1.0
Deferred Long Term Liab	-0.23	-0.08	0.36	-0.38	0.79	-0.3	-0.37	0.49	-0.26	-0.38	-0.36	-0.18	0.46	0.2	-0.35	-0.47	-0.34	0.14	-0.46	0.61	0.1	1.0	1.0

Click cells to compare fundamentals

In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.

Competition

Predict Bioventus

Ebitda Over Time

Bioventus Ebitda

Ebitda

(21.92 Million)

At this time, Bioventus' EBITDA is comparatively stable compared to the past year.

According to the company disclosure, Bioventus reported earnings before interest,tax, depreciation and amortization of (23.07 Million). This is 102.63% lower than that of the Health Care Equipment & Supplies sector and 103.59% lower than that of the Health Care industry. The ebitda for all United States stocks is 100.59% higher than that of the company.

Bioventus EBITDA Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Bioventus' direct or indirect competition against its EBITDA to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Bioventus could also be used in its relative valuation, which is a method of valuing Bioventus by comparing valuation metrics of similar companies.

Bioventus is currently under evaluation in ebitda category among its peers.

Bioventus Current Valuation Drivers

We derive many important indicators used in calculating different scores of Bioventus from analyzing Bioventus' financial statements. These drivers represent accounts that assess Bioventus' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Bioventus' important valuation drivers and their relationship over time.

		2019	2020	2021	2022	2023	2024 (projected)
Enterprise Value		1.2B	1.2B	1.2B	546.5M	688.0M	1.2B

Bioventus ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Bioventus' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Bioventus' managers, analysts, and investors.

Environmental

Governance

Social

Bioventus Institutional Holders

Institutional Holdings refers to the ownership stake in Bioventus that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Bioventus' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Bioventus' value.

		Shares
Ophir Asset Management Pty Ltd	2024-09-30	524.2 K
State Street Corp	2024-06-30	487.3 K
Charles Schwab Investment Management Inc	2024-09-30	390.2 K
Renaissance Technologies Corp	2024-09-30	387.9 K
Oberweis Asset Management Inc	2024-06-30	380.9 K
Segall Bryant & Hamill	2024-09-30	377.8 K
Pura Vida Investments, Llc	2024-09-30	352.6 K
Marshall Wace Asset Management Ltd	2024-06-30	332.3 K
Northern Trust Corp	2024-09-30	322.4 K
Essex Woodlands Health Ventures	2024-09-30	13 M
Nantahala Capital Management, Llc	2024-06-30	10.7 M

Bioventus Fundamentals

	Return On Equity	-0.25
	Return On Asset	0.0248
	Profit Margin	(0.07) %
	Operating Margin	0.05 %
	Current Valuation	1.09 B
	Shares Outstanding	65.37 M
	Shares Owned By Insiders	11.47 %
	Shares Owned By Institutions	69.76 %
	Number Of Shares Shorted	1.34 M
	Price To Earning	6.96 X
	Price To Book	5.01 X
	Price To Sales	1.34 X
	Revenue	512.35 M
	Gross Profit	302.71 M
	EBITDA	(23.07 M)
	Net Income	(96.74 M)
	Cash And Equivalents	34.36 M
	Cash Per Share	0.56 X
	Total Debt	394.85 M
	Debt To Equity	1.17 %
	Current Ratio	0.94 X
	Book Value Per Share	2.28 X
	Cash Flow From Operations	15.34 M
	Short Ratio	3.57 X
	Earnings Per Share	(0.61) X
	Price To Earnings To Growth	2.14 X
	Target Price	14.67
	Number Of Employees	1.03 K
	Beta	0.88
	Market Capitalization	745.85 M
	Total Asset	810.91 M
	Retained Earnings	(321.54 M)
	Working Capital	92.5 M
	Net Asset	810.91 M

About Bioventus Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Bioventus's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Bioventus using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Bioventus based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Bioventus Stock Analysis

When running Bioventus' price analysis, check to measure Bioventus' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bioventus is operating at the current time. Most of Bioventus' value examination focuses on studying past and present price action to predict the probability of Bioventus' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bioventus' price. Additionally, you may evaluate how the addition of Bioventus to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC